Literature DB >> 24889767

Gastric cancer drug trials - are women second class citizens?

Lishi Wang1, Yan Jiao1, Yun Jiao2, Yanhong Cao3, Weikuan Gu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24889767     DOI： 10.1038/nrclinonc.2013.231-c1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  13 in total

1.  Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era.

Authors:  Manish A Shah
Journal:  Nat Rev Clin Oncol       Date:  2013-12-03       Impact factor: 66.675

2.  Prospective randomized trial of preoperative enteral immunonutrition followed by elective total gastrectomy for gastric cancer.

Authors:  K Fujitani; T Tsujinaka; J Fujita; I Miyashiro; H Imamura; Y Kimura; K Kobayashi; Y Kurokawa; T Shimokawa; H Furukawa
Journal:  Br J Surg       Date:  2012-02-24       Impact factor: 6.939

3.  Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity.

Authors:  Dongyun Yang; Andrew Hendifar; Cosima Lenz; Kayo Togawa; Felicitas Lenz; Georg Lurje; Alexandra Pohl; Thomas Winder; Yan Ning; Susan Groshen; Heinz-Josef Lenz
Journal:  J Gastrointest Oncol       Date:  2011-06

Review 4.  Differential expression of biomarkers in men and women.

Authors:  David Planchard; Yohann Loriot; Aicha Goubar; Fréderic Commo; Jean-Charles Soria
Journal:  Semin Oncol       Date:  2009-12       Impact factor: 4.929

5.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Young-Woo Kim; Han-Kwang Yang; Hyun Cheol Chung; Young-Kyu Park; Kyung Hee Lee; Keun-Wook Lee; Yong Ho Kim; Sang-Ik Noh; Jae Yong Cho; Young Jae Mok; Yeul Hong Kim; Jiafu Ji; Ta-Sen Yeh; Peter Button; Florin Sirzén; Sung Hoon Noh
Journal:  Lancet       Date:  2012-01-07       Impact factor: 79.321

6.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study.

Authors:  Freddie Bray; Ahmedin Jemal; Nathan Grey; Jacques Ferlay; David Forman
Journal:  Lancet Oncol       Date:  2012-06-01       Impact factor: 41.316

7.  Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

Authors:  Charles S Fuchs; Jiri Tomasek; Cho Jae Yong; Filip Dumitru; Rodolfo Passalacqua; Chanchal Goswami; Howard Safran; Lucas Vieira Dos Santos; Giuseppe Aprile; David R Ferry; Bohuslav Melichar; Mustapha Tehfe; Eldar Topuzov; John Raymond Zalcberg; Ian Chau; William Campbell; Choondal Sivanandan; Joanna Pikiel; Minori Koshiji; Yanzhi Hsu; Astra M Liepa; Ling Gao; Jonathan D Schwartz; Josep Tabernero
Journal:  Lancet       Date:  2013-10-03       Impact factor: 79.321

8.  Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980.

Authors:  C Bosetti; P Bertuccio; M Malvezzi; F Levi; L Chatenoud; E Negri; C La Vecchia
Journal:  Ann Oncol       Date:  2013-08-06       Impact factor: 32.976

9.  Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201).

Authors:  Y-K Kang; H-M Chang; J H Yook; M-H Ryu; I Park; Y J Min; D Y Zang; G Y Kim; D H Yang; S J Jang; Y S Park; J-L Lee; T W Kim; S T Oh; B K Park; H-Y Jung; B S Kim
Journal:  Br J Cancer       Date:  2013-02-28       Impact factor: 7.640

10.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.

Authors:  Tom Waddell; Ian Chau; David Cunningham; David Gonzalez; Alicia Frances Clare Okines; Alicia Frances; Clare Okines; Andrew Wotherspoon; Claire Saffery; Gary Middleton; Jonathan Wadsley; David Ferry; Wasat Mansoor; Tom Crosby; Fareeda Coxon; David Smith; Justin Waters; Timothy Iveson; Stephen Falk; Sarah Slater; Clare Peckitt; Yolanda Barbachano
Journal:  Lancet Oncol       Date:  2013-04-15       Impact factor: 41.316
View more
  2 in total

1.  Gastric cancer drug trials - are women second class citizens?

Authors:  Manish A Shah
Journal:  Nat Rev Clin Oncol       Date:  2014-06-03       Impact factor: 66.675

Review 2.  Esophageal Cancer: Should Gender Be Considered as an Influential Factor for Patient Safety in Drug Treatment?

Authors:  Fengxia Liu; Helin Feng; Sumin Guo; Yuhan Chen; Qingyi Liu; Feng Wu; Weikuan Gu; Baoen Shan
Journal:  J Oncol       Date:  2019-05-23       Impact factor: 4.375
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.